Current strategies for CD8+ T-cell-based strategies to treat or cure HIV infection are based on stimulating pre-existing and/or inducing de novo HIV-specific immune responses through vaccine therapies or redirecting HIV-specific CD8+ T-cells and improving their function and persistence after adoptive transfer. This evidence concerns the gene CD8A and HIV infectious disease.